Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:133470739" >
CYP2B6 genotype-bas...
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population
-
Mukonzo, JK (författare)
-
Bisaso, RK (författare)
-
Ogwal-Okeng, J (författare)
-
visa fler...
-
- Gustafsson, LL (författare)
- Karolinska Institutet
-
Owen, JS (författare)
-
- Aklillu, E (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Future Medicine Ltd, 2016
- 2016
- Engelska.
-
Ingår i: Pharmacogenomics. - : Future Medicine Ltd. - 1744-8042 .- 1462-2416. ; 17:6, s. 603-613
- Relaterad länk:
-
http://kipublication...
-
visa fler...
-
https://doi.org/10.2...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aim: To assess genotype effect on efavirenz (EFV) pharmacokinetics, treatment outcomes and provide genotype-based EFV doses recommendations during for tuberculosis (TB)-HIV-1 cotreatment. Materials & methods: EFV concentrations from 158 HIV-TB co-infected patients treated with EFV/lamivudine/zidovidine and rifampicin were analyzed. Genotype and CD4 and viral load data were analyzed using a population PK model. Results: Simulated AUCs for 600 mg EFV dose were 1.2- and 2.4-times greater than the product label for Ugandans in general and CYP2B6*6/*6 genotypes respectively. EFV daily doses of 450 and 250 mg for Ugandans and CYP2B6*6/*6 genotypes, respectively, yielded simulated exposures comparable to the product label. Conclusions: Around 450 and 250 mg daily doses might meet EFV dosing needs of HIV-TB infected Ugandans in general and CYP2B6*6/*6 genotypes, respectively.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas